Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies

Annals of Neurology

Volumn 35, Issue 3, 1994, Pages 304-311

  Chaudhry, Vinay ^a   Rowinsky, Eric K ^a   Sartorius, Susan E ^a   Donehower, Ross C ^a   Cornblath, David R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PERONEUS NERVE; PRIORITY JOURNAL; SCORING SYSTEM; SENSORIMOTOR NEUROPATHY; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURAL NERVE; SYMPTOMATOLOGY; VIBRATION SENSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX; VIBRATION;

EID: 0028270476     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410350310     Document Type: Article

References (20)

1. Sequences of taxol and cisplatin: a phase I and pharmacologic study
2. Phase I study of taxol and granulocyte colony‐stimulating factor in patients with refractory ovarian cancer
3. Phase II study and long‐term follow‐up of patients treated with taxol for advanced ovarian adenocarcinoma
4. A phase I and pharmacologic study of taxol and cisplatin with granulocyte colony‐stimulating factor: neuromuscular toxicity is doselimiting
5. Peripheral sensory neuropathy and cisplastin chemotherapy
6. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies
7. Cisplatin neuropathy: risk factors, prognosis, and protection by WR‐2721
8. Phase I clinical and pharmacokinetic study of taxol
9. Phase I trial of taxol given as a 24‐hour infusion every 21 days: responses observed in metastatic melanoma
10. Taxol produces a predominantly sensory neuropathy
11. Pathology of neurotoxic axonal degeneration
12. Toxic neuropathies
13. Pyridoxine neuropathy in rats: specific degeneration of sensory axons
14. Dose‐dependent expression of neuronopathy after experimental pyridoxine intoxication
15. Nerve growth factor revisited
16. Nerve growth factor and regeneration of peripheral nervous system
17. Nerve growth factor attenuates neurotoxic effects of taxol in spinal‐area ganglion explants from fetal mice
18. Nerve growth factor prevents toxic neuropathy in mice
19. Nerve growth factor prevents experimental cisplatin neuropathy
20. The ACTH‐(4‐9) analog, ORG 2766, prevents taxol‐induced neuropathy in rats